Objective: Ovarian cancer is the most lethal gynecologic neoplasm in females. In ovarian cancer, FOXA1 aids transcription of YAP associated protein mediated by the cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB). As a result, cellular proliferation and migration increased. The roles of Eph receptors and ephrin ligands in cell adhesion, migration, cell proliferation regulation in various cancers, and angiogenesis are well characterized. Material and Methods: This study included formalin-fixed, paraffin-embedded tissue specimens from 41 patients with ovarian serous cystadenocarcinoma, including both low and high grade tumors. For each case, a paraffin block with tumor tissue was chosen for an immunohistochemical procedure using primary antibodies against EphA5 and FOXA1. By the end of 2017, patients finished their chemotherapy and were followed for the next 3 years. Results: Positive FOXA1 and EphA5 results were presented in 68.3% and 39% of patients respectively. A statistically significant correlation was detected between FOXA1 expression and each of CA-125 level, tumor stage, tumor grade, and presence of lymph node metastasis. In our work, the OS was positively correlated to EphA5 expression and inversely correlated to FOXA1 immunoreactivity. The estimated DFS and EphA5 immunoreactivity had a significant positive association, whereas DFS and FOXA1 protein expression had a significant inverse link. Conclusion: FOXA1 and EphA5 expression have a role in ovarian cancer progression and prognosis prediction.